Published
{
"ticker": "TECH",
"cik": "0000842023",
"company": "Bio-Techne Corporation",
"business_type": "life sciences tools and diagnostics",
"schema_template": "standard operating company (net sales, cost of sales, gross margin, operating income, net earnings; cash, debt, assets, equity; operating cash flow, capital expenditures, free cash flow)",
"reporting_currency": "USD",
"converted_to_usd": false,
"units": "actual dollars (not thousands); per-share amounts in dollars; share counts in actual shares",
"units_notes_seen": {
"FY2026 10-K consolidated statements of earnings and comprehensive income": "(in thousands, except per share data)",
"FY2026 10-K consolidated balance sheets": "(in thousands, except share and per share data)",
"FY2026 10-K consolidated statements of shareholders' equity": "(in thousands)",
"FY2026 10-K consolidated statements of cash flows": "(in thousands)",
"FY2026 10-K segment information (Note 13)": "(in thousands)",
"FY2026 10-K revenue disaggregation (Note 2)": "(in thousands)",
"Q3 FY2026 10-Q condensed consolidated statements of earnings and comprehensive income": "(in thousands, except per share data)",
"Q3 FY2026 10-Q condensed consolidated balance sheets": "(in thousands, except share and per share data)",
"Q3 FY2026 10-Q condensed consolidated statements of cash flows": "(in thousands)",
"Fourth-quarter and full-year fiscal 2026 earnings release, condensed consolidated statements of earnings (Exhibit 99.1)": "(In thousands, except per share data)"
},
"adjustments": {
"splits_applied": [],
"adr_ratio": null,
"fx": "none - the company reports in U.S. dollars"
},
"annual": [
{
"fiscal_year": 2026,
"label": "FY2026",
"period_start": "2025-07-01",
"period_end": "2026-06-30",
"period_type": "fiscal year",
"source_accession": "0001104659-26-100322",
"income_statement": {
"net_sales": 1215039000,
"cost_of_sales": 415968000,
"gross_margin": 799071000,
"selling_general_and_administrative": 452415000,
"research_and_development": 94766000,
"total_operating_expenses": 547181000,
"operating_income": 251890000,
"interest_expense": -9630000,
"interest_income": 4223000,
"total_other_income_expense_net": -11210000,
"earnings_before_income_taxes": 240680000,
"income_taxes": 58818000,
"net_earnings": 181862000,
"basic_eps": 1.17,
"diluted_eps": 1.16,
"basic_shares": 155963000,
"diluted_shares": 157009000,
"dividends_declared_per_share": 0.32
},
"balance_sheet": {
"cash_and_cash_equivalents": 264712000,
"accounts_receivable_net": 216585000,
"inventories": 195744000,
"total_current_assets": 744401000,
"property_and_equipment_net": 231836000,
"goodwill": 975355000,
"intangible_assets_net": 303465000,
"total_assets": 2586726000,
"total_current_liabilities": 163700000,
"long_term_debt": 200000000,
"total_shareholders_equity": 2108221000,
"total_debt": 200000000,
"total_liabilities": 478505000,
"shares_issued_and_outstanding": 156095113
},
"cash_flow": {
"net_earnings": 181862000,
"depreciation_and_amortization": 97359000,
"stock_based_compensation": 41365000,
"operating_cash_flow": 292073000,
"capex": -28850000,
"net_cash_used_in_investing_activities": -18190000,
"cash_dividends_paid": -49916000,
"repurchases_of_common_stock": -41675000,
"net_cash_used_in_financing_activities": -169114000,
"cash_and_cash_equivalents_at_end_of_period": 264712000,
"free_cash_flow": 263223000
},
"segment_results": {
"protein_sciences": {
"net_sales": 874620000,
"segment_operating_income": 359401000
},
"diagnostics_and_spatial_biology": {
"net_sales": 336365000,
"segment_operating_income": 37698000
},
"total_reportable_segment_net_sales": 1210985000,
"total_segment_operating_income": 397099000
},
"revenue_by_type": {
"consumables": 985115000,
"instruments": 110632000,
"services": 94301000,
"royalties": 24991000,
"total_net_sales": 1215039000
},
"revenue_by_geography": {
"united_states": 635372000,
"emea_excluding_united_kingdom": 294222000,
"united_kingdom": 56284000,
"apac_excluding_greater_china": 85815000,
"greater_china": 104061000,
"rest_of_world": 39285000,
"total_net_sales": 1215039000
}
},
{
"fiscal_year": 2025,
"label": "FY2025",
"period_start": "2024-07-01",
"period_end": "2025-06-30",
"period_type": "fiscal year",
"source_accession": "0001104659-26-100322",
"income_statement": {
"net_sales": 1219635000,
"cost_of_sales": 429363000,
"gross_margin": 790272000,
"selling_general_and_administrative": 588521000,
"research_and_development": 99496000,
"total_operating_expenses": 688017000,
"operating_income": 102255000,
"interest_expense": -8509000,
"interest_income": 3886000,
"total_other_income_expense_net": -3792000,
"earnings_before_income_taxes": 98463000,
"income_taxes": 25063000,
"net_earnings": 73400000,
"basic_eps": 0.47,
"diluted_eps": 0.46,
"basic_shares": 157521000,
"diluted_shares": 159717000,
"dividends_declared_per_share": 0.32
},
"balance_sheet": {
"cash_and_cash_equivalents": 162186000,
"accounts_receivable_net": 206876000,
"inventories": 189446000,
"total_current_assets": 608300000,
"property_and_equipment_net": 245719000,
"goodwill": 980935000,
"intangible_assets_net": 365599000,
"total_assets": 2557868000,
"total_current_liabilities": 175849000,
"long_term_debt": 346000000,
"total_shareholders_equity": 1918808000,
"total_debt": 346000000,
"total_liabilities": 639060000,
"shares_issued_and_outstanding": 154972196
},
"cash_flow": {
"net_earnings": 73400000,
"depreciation_and_amortization": 109903000,
"stock_based_compensation": 40833000,
"operating_cash_flow": 287556000,
"capex": -31006000,
"net_cash_used_in_investing_activities": -35183000,
"cash_dividends_paid": -50391000,
"repurchases_of_common_stock": -275731000,
"net_cash_used_in_financing_activities": -253905000,
"cash_and_cash_equivalents_at_end_of_period": 162186000,
"free_cash_flow": 256550000
},
"segment_results": {
"protein_sciences": {
"net_sales": 870245000,
"segment_operating_income": 370353000
},
"diagnostics_and_spatial_biology": {
"net_sales": 346263000,
"segment_operating_income": 21324000
},
"total_reportable_segment_net_sales": 1216508000,
"total_segment_operating_income": 391677000
},
"revenue_by_type": {
"consumables": 972286000,
"instruments": 112086000,
"services": 111570000,
"royalties": 23693000,
"total_net_sales": 1219635000
},
"revenue_by_geography": {
"united_states": 683230000,
"emea_excluding_united_kingdom": 266305000,
"united_kingdom": 54827000,
"apac_excluding_greater_china": 77263000,
"greater_china": 100463000,
"rest_of_world": 37547000,
"total_net_sales": 1219635000
}
},
{
"fiscal_year": 2024,
"label": "FY2024",
"period_start": "2023-07-01",
"period_end": "2024-06-30",
"period_type": "fiscal year",
"source_accession": "0001104659-26-100322",
"income_statement": {
"net_sales": 1159060000,
"cost_of_sales": 389335000,
"gross_margin": 769725000,
"selling_general_and_administrative": 466375000,
"research_and_development": 96664000,
"total_operating_expenses": 563039000,
"operating_income": 206686000,
"interest_expense": -15736000,
"interest_income": 3323000,
"total_other_income_expense_net": -20997000,
"earnings_before_income_taxes": 185689000,
"income_taxes": 17584000,
"net_earnings": 168105000,
"basic_eps": 1.07,
"diluted_eps": 1.05,
"basic_shares": 157708000,
"diluted_shares": 160774000,
"dividends_declared_per_share": 0.32
},
"balance_sheet": {
"total_shareholders_equity": 2068850000,
"shares_issued_and_outstanding": 158216000
},
"cash_flow": {
"net_earnings": 168105000,
"depreciation_and_amortization": 111711000,
"stock_based_compensation": 38042000,
"operating_cash_flow": 298981000,
"capex": -62877000,
"net_cash_used_in_investing_activities": -203030000,
"cash_dividends_paid": -50419000,
"repurchases_of_common_stock": -80042000,
"net_cash_used_in_financing_activities": -122398000,
"cash_and_cash_equivalents_at_end_of_period": 151791000,
"free_cash_flow": 236104000
},
"segment_results": {
"protein_sciences": {
"net_sales": 830902000,
"segment_operating_income": 354775000
},
"diagnostics_and_spatial_biology": {
"net_sales": 326392000,
"segment_operating_income": 24546000
},
"total_reportable_segment_net_sales": 1157294000,
"total_segment_operating_income": 379321000
},
"revenue_by_type": {
"consumables": 928180000,
"instruments": 108270000,
"services": 99265000,
"royalties": 23345000,
"total_net_sales": 1159060000
},
"revenue_by_geography": {
"united_states": 657747000,
"emea_excluding_united_kingdom": 241432000,
"united_kingdom": 50012000,
"apac_excluding_greater_china": 73904000,
"greater_china": 99467000,
"rest_of_world": 36498000,
"total_net_sales": 1159060000
},
"source_note": "Income statement and cash flow from the fiscal 2026 10-K. The 10-K's balance sheets cover only June 30, 2026 and 2025, so the only June 30, 2024 balance-sheet amounts reported here are total shareholders' equity and shares outstanding, taken from the consolidated statements of shareholders' equity in the same 10-K."
}
],
"quarterly": [
{
"fiscal_year": 2026,
"fiscal_quarter": 4,
"label": "Q4 FY2026",
"period_start": "2026-04-01",
"period_end": "2026-06-30",
"period_type": "three months",
"source_accession": "0001104659-26-094391",
"income_statement": {
"net_sales": 321191000,
"cost_of_sales": 109797000,
"gross_margin": 211394000,
"selling_general_and_administrative": 113172000,
"research_and_development": 23945000,
"total_operating_expenses": 137117000,
"operating_income": 74277000,
"total_other_income_expense_net": -3596000,
"earnings_before_income_taxes": 70681000,
"income_taxes": 16059000,
"net_earnings": 54622000,
"basic_eps": 0.35,
"diluted_eps": 0.35,
"basic_shares": 156090000,
"diluted_shares": 157025000
},
"balance_sheet": {
"cash_and_cash_equivalents": 264712000,
"accounts_receivable_net": 216585000,
"inventories": 195744000,
"total_current_assets": 744401000,
"property_and_equipment_net": 231836000,
"goodwill": 975355000,
"intangible_assets_net": 303465000,
"total_assets": 2586726000,
"total_current_liabilities": 163700000,
"long_term_debt": 200000000,
"total_shareholders_equity": 2108221000,
"total_debt": 200000000,
"total_liabilities": 478505000,
"shares_issued_and_outstanding": 156095113
},
"cash_flow": {
"depreciation_and_amortization": 24141000,
"stock_based_compensation": 5230000,
"operating_cash_flow": 95416000,
"capex": -8480000,
"free_cash_flow": 86936000,
"net_cash_used_in_investing_activities": -7057000,
"cash_dividends_paid": -12484000,
"repurchases_of_common_stock": -41651000,
"net_cash_used_in_financing_activities": -33208000,
"cash_and_cash_equivalents_at_end_of_period": 264712000
},
"additional_source_accessions": [
"0001104659-26-100322",
"0001104659-26-056302"
],
"source_note": "Income statement from the earnings release furnished on Form 8-K on August 12, 2026 (accession 0001104659-26-094391); balance sheet from the fiscal 2026 10-K (accession 0001104659-26-100322); cash flow derived from the 10-K's fiscal-year column less the nine-month column in the third-quarter fiscal 2026 10-Q (accession 0001104659-26-056302)."
},
{
"fiscal_year": 2026,
"fiscal_quarter": 3,
"label": "Q3 FY2026",
"period_start": "2026-01-01",
"period_end": "2026-03-31",
"period_type": "three months",
"source_accession": "0001104659-26-056302",
"income_statement": {
"net_sales": 311415000,
"cost_of_sales": 103127000,
"gross_margin": 208288000,
"selling_general_and_administrative": 109338000,
"research_and_development": 23455000,
"total_operating_expenses": 132793000,
"operating_income": 75495000,
"total_other_income_expense_net": -4270000,
"earnings_before_income_taxes": 71225000,
"income_taxes": 20178000,
"net_earnings": 51047000,
"basic_eps": 0.33,
"diluted_eps": 0.32,
"basic_shares": 156327000,
"diluted_shares": 157403000
},
"balance_sheet": {
"cash_and_cash_equivalents": 209819000,
"accounts_receivable_net": 214562000,
"inventories": 201175000,
"total_current_assets": 688050000,
"property_and_equipment_net": 232990000,
"goodwill": 977800000,
"intangible_assets_net": 319074000,
"total_assets": 2550601000,
"total_current_liabilities": 153278000,
"long_term_debt": 200000000,
"total_shareholders_equity": 2085304000,
"total_debt": 200000000,
"total_liabilities": 465297000,
"shares_issued_and_outstanding": 156516091
}
},
{
"fiscal_year": 2025,
"fiscal_quarter": 4,
"label": "Q4 FY2025",
"period_start": "2025-04-01",
"period_end": "2025-06-30",
"period_type": "three months",
"source_accession": "0001104659-26-094391",
"income_statement": {
"net_sales": 316964000,
"cost_of_sales": 118152000,
"gross_margin": 198812000,
"selling_general_and_administrative": 196640000,
"research_and_development": 26032000,
"total_operating_expenses": 222672000,
"operating_income": -23860000,
"total_other_income_expense_net": 1001000,
"earnings_before_income_taxes": -22859000,
"income_taxes": -5182000,
"net_earnings": -17677000,
"basic_eps": -0.11,
"diluted_eps": -0.11,
"basic_shares": 154913000,
"diluted_shares": 155757000
},
"balance_sheet": {
"cash_and_cash_equivalents": 162186000,
"accounts_receivable_net": 206876000,
"inventories": 189446000,
"total_current_assets": 608300000,
"property_and_equipment_net": 245719000,
"goodwill": 980935000,
"intangible_assets_net": 365599000,
"total_assets": 2557868000,
"total_current_liabilities": 175849000,
"long_term_debt": 346000000,
"total_shareholders_equity": 1918808000,
"total_debt": 346000000,
"total_liabilities": 639060000,
"shares_issued_and_outstanding": 154972196
},
"cash_flow": {
"depreciation_and_amortization": 27111000,
"stock_based_compensation": 4550000,
"operating_cash_flow": 98201000,
"capex": -4890000,
"free_cash_flow": 93311000,
"net_cash_used_in_investing_activities": 406000,
"cash_dividends_paid": -12387000,
"repurchases_of_common_stock": -100057000,
"net_cash_used_in_financing_activities": -90452000,
"cash_and_cash_equivalents_at_end_of_period": 162186000
},
"additional_source_accessions": [
"0001104659-26-100322",
"0001104659-26-056302"
],
"source_note": "Income statement from the earnings release furnished on Form 8-K on August 12, 2026 (accession 0001104659-26-094391); balance sheet from the fiscal 2026 10-K (accession 0001104659-26-100322); cash flow derived from the 10-K's fiscal-year column less the nine-month column in the third-quarter fiscal 2026 10-Q (accession 0001104659-26-056302)."
},
{
"fiscal_year": 2025,
"fiscal_quarter": 3,
"label": "Q3 FY2025",
"period_start": "2025-01-01",
"period_end": "2025-03-31",
"period_type": "three months",
"source_accession": "0001104659-26-056302",
"income_statement": {
"net_sales": 316181000,
"cost_of_sales": 101625000,
"gross_margin": 214556000,
"selling_general_and_administrative": 151269000,
"research_and_development": 24579000,
"total_operating_expenses": 175848000,
"operating_income": 38708000,
"total_other_income_expense_net": -434000,
"earnings_before_income_taxes": 38274000,
"income_taxes": 15686000,
"net_earnings": 22588000,
"basic_eps": 0.14,
"diluted_eps": 0.14,
"basic_shares": 157372000,
"diluted_shares": 158944000
}
}
],
"year_to_date": {
"label": "Nine months ended March 31, 2026",
"period_start": "2025-07-01",
"period_end": "2026-03-31",
"period_type": "nine months",
"source_accession": "0001104659-26-056302",
"prior_year_comparative": {
"label": "Nine months ended March 31, 2025",
"period_start": "2024-07-01",
"period_end": "2025-03-31",
"period_type": "nine months",
"source_accession": "0001104659-26-056302",
"income_statement": {
"net_sales": 902671000.0,
"cost_of_sales": 311211000.0,
"gross_margin": 591460000.0,
"selling_general_and_administrative": 391881000.0,
"research_and_development": 73464000.0,
"total_operating_expenses": 465345000.0,
"operating_income": 126115000.0,
"total_other_income_expense_net": -4793000.0,
"earnings_before_income_taxes": 121322000.0,
"income_taxes": 30244000.0,
"net_earnings": 91078000.0,
"basic_eps": 0.58,
"diluted_eps": 0.57,
"basic_shares": 158117000.0,
"diluted_shares": 160662000.0
},
"cash_flow": {
"net_earnings": 91078000.0,
"depreciation_and_amortization": 82792000.0,
"stock_based_compensation": 36283000.0,
"operating_cash_flow": 189355000.0,
"capex": -26116000.0,
"free_cash_flow": 163239000.0,
"net_cash_used_in_investing_activities": -35589000.0,
"cash_dividends_paid": -38004000.0,
"repurchases_of_common_stock": -175674000.0,
"net_cash_used_in_financing_activities": -163453000.0,
"cash_and_cash_equivalents_at_end_of_period": 140670000.0
}
},
"income_statement": {
"net_sales": 893847000.0,
"cost_of_sales": 306170000.0,
"gross_margin": 587677000.0,
"selling_general_and_administrative": 339242000.0,
"research_and_development": 70821000.0,
"total_operating_expenses": 410063000.0,
"operating_income": 177614000.0,
"total_other_income_expense_net": -7614000.0,
"earnings_before_income_taxes": 170000000.0,
"income_taxes": 42759000.0,
"net_earnings": 127241000.0,
"basic_eps": 0.82,
"diluted_eps": 0.81,
"basic_shares": 155893000.0,
"diluted_shares": 156943000.0
},
"cash_flow": {
"net_earnings": 127241000.0,
"depreciation_and_amortization": 73218000.0,
"stock_based_compensation": 36135000.0,
"operating_cash_flow": 196657000.0,
"capex": -20370000.0,
"free_cash_flow": 176287000.0,
"net_cash_used_in_investing_activities": -11133000.0,
"cash_dividends_paid": -37432000.0,
"repurchases_of_common_stock": -24000.0,
"net_cash_used_in_financing_activities": -135906000.0,
"cash_and_cash_equivalents_at_end_of_period": 209819000.0
}
},
"trailing_twelve_months": {
"label": "Trailing twelve months ended June 30, 2026",
"period_start": "2025-07-01",
"period_end": "2026-06-30",
"period_type": "twelve months",
"source_accession": "0001104659-26-100322",
"income_statement": {
"net_sales": 1215039000,
"cost_of_sales": 415968000,
"gross_margin": 799071000,
"selling_general_and_administrative": 452415000,
"research_and_development": 94766000,
"total_operating_expenses": 547181000,
"operating_income": 251890000,
"interest_expense": -9630000,
"interest_income": 4223000,
"total_other_income_expense_net": -11210000,
"earnings_before_income_taxes": 240680000,
"income_taxes": 58818000,
"net_earnings": 181862000,
"basic_eps": 1.17,
"diluted_eps": 1.16,
"basic_shares": 155963000,
"diluted_shares": 157009000,
"dividends_declared_per_share": 0.32
},
"balance_sheet": {
"cash_and_cash_equivalents": 264712000,
"accounts_receivable_net": 216585000,
"inventories": 195744000,
"total_current_assets": 744401000,
"property_and_equipment_net": 231836000,
"goodwill": 975355000,
"intangible_assets_net": 303465000,
"total_assets": 2586726000,
"total_current_liabilities": 163700000,
"long_term_debt": 200000000,
"total_shareholders_equity": 2108221000,
"total_debt": 200000000,
"total_liabilities": 478505000,
"shares_issued_and_outstanding": 156095113
},
"cash_flow": {
"net_earnings": 181862000,
"depreciation_and_amortization": 97359000,
"stock_based_compensation": 41365000,
"operating_cash_flow": 292073000,
"capex": -28850000,
"net_cash_used_in_investing_activities": -18190000,
"cash_dividends_paid": -49916000,
"repurchases_of_common_stock": -41675000,
"net_cash_used_in_financing_activities": -169114000,
"cash_and_cash_equivalents_at_end_of_period": 264712000,
"free_cash_flow": 263223000
}
},
"notes": [
"Fiscal 2026, 2025 and 2024 income statement and cash flow figures, and the June 30, 2026 and June 30, 2025 balance sheets, are taken from the consolidated financial statements in the fiscal 2026 Form 10-K (accession 0001104659-26-100322), filed August 24, 2026. Bio-Techne's fiscal year ends June 30.",
"The 10-K presents its statements in thousands; every figure in this record is stated in actual U.S. dollars.",
"The consolidated balance sheets in the 10-K present only June 30, 2026 and June 30, 2025. Fiscal 2024 therefore carries no balance sheet here apart from total shareholders' equity and shares outstanding at June 30, 2024, which the consolidated statements of shareholders' equity print.",
"Bio-Techne does not file a fourth-quarter 10-Q. The Q4 fiscal 2026 and Q4 fiscal 2025 income statements are taken from the condensed consolidated statements of earnings in Exhibit 99.1 to the earnings release furnished on Form 8-K on August 12, 2026 (accession 0001104659-26-094391), which prints an explicit quarter-ended June 30 column for both years. These are press-release figures, not figures from a quarterly report.",
"The Q4 cash flow figures for both years are derived by subtracting the nine months ended March 31 (from the third-quarter fiscal 2026 Form 10-Q, accession 0001104659-26-056302) from the corresponding fiscal year in the 10-K. No filing prints a discrete fourth-quarter cash flow statement.",
"Deriving the fourth quarter the same way from the income statement reproduces the earnings release to within one thousand dollars on net sales, cost of sales, operating income, income taxes and net earnings, which is rounding at the thousand-dollar level. The earnings release's own quarterly column is the figure reported here.",
"Third-quarter figures for fiscal 2026 and fiscal 2025 come from the third-quarter fiscal 2026 Form 10-Q (accession 0001104659-26-056302), which prints the quarter and the nine months side by side. Only the discrete three-month columns are reported as quarters; the nine-month columns are reported separately in the year-to-date block.",
"Because fiscal 2026 closed on June 30, 2026, the year-to-date block reports the nine months ended March 31, 2026 as the 10-Q prints it. The completed fiscal year is the FY2026 entry in the annual list, and the trailing twelve months ended June 30, 2026 coincide exactly with fiscal 2026.",
"Total liabilities is not printed as a subtotal on Bio-Techne's balance sheet. It is stated here as total assets less total shareholders' equity, and agrees with the sum of the individual liability captions.",
"Total debt equals long-term debt obligations. The balance sheets present no current portion of debt. Long-term borrowings fell from $346.0 million at June 30, 2025 to $200.0 million at June 30, 2026 on $146.0 million of repayments.",
"Cash outflows are carried with the sign the statements print, so capital expenditures and dividends are negative. Free cash flow is operating cash flow less the cash spent on property and equipment.",
"Fiscal 2025 operating income of $102.3 million was depressed by an $80.5 million impairment of assets held-for-sale and $41.8 million of certain litigation charges, chiefly $37.2 million paid on a binding arbitration award resolving a dispute with the company's former chief executive over the expiration of stock options. The 10-K states that amount is inclusive of interest and legal fees; the Form 8-K of March 4, 2025 (accession 0001558370-25-002177) reports the arbitrator's award itself as approximately $35,978,000, plus approximately $980,000 of interest and approximately $234,000 of legal fees and costs. Fiscal 2026 includes a $6.8 million recovery on those held-for-sale assets and $5.5 million of litigation charges. This is the main reason fiscal 2025 net earnings of $73.4 million sit well below both fiscal 2024 and fiscal 2026.",
"On June 25, 2026 Bio-Techne entered into a merger agreement under which Merck KGaA, Darmstadt, Germany would acquire each outstanding share for $73.00 in cash. The merger was pending at the date of the 10-K, is subject to shareholder and antitrust approvals, and is expected to close by late 2026 or early 2027. The 10-K's income statement carries no separate line for costs of the pending merger.",
"Segment operating income is stated before amortization of intangibles, acquisition-related expenses, certain litigation charges, stock-based compensation, restructuring costs, the impact of a business held-for-sale and corporate general and administrative expenses, so the two segments do not sum to consolidated operating income. Note 13 of the 10-K carries the full reconciliation.",
"Reportable-segment net sales ($1,210,985 thousand in fiscal 2026) exclude a business classified as held-for-sale and intersegment eliminations, which is why they differ from consolidated net sales of $1,215,039 thousand.",
"Cash dividends declared were $0.32 per share in each of fiscal 2026, 2025 and 2024.",
"Bio-Techne's 4-for-1 forward stock split was effective November 30, 2022, before every period reported here, and all per-share amounts in these filings are already stated on a post-split basis. No split adjustment has been applied.",
"Bio-Techne reports in U.S. dollars and is not an American depositary receipt issuer, so no currency conversion or per-ADS adjustment applies."
],
"uncertainties": [
"The fourth-quarter income statements for fiscal 2026 and fiscal 2025 are press-release figures from the August 12, 2026 Form 8-K rather than figures from a quarterly report. Deriving the same quarters by subtracting the 10-Q's nine-month columns from the 10-K's fiscal-year columns gives net sales, cost of sales, operating income, income taxes and net earnings that differ by one thousand dollars; the gap is rounding and does not change any figure at the precision reported.",
"Neither the fiscal 2026 10-K nor the third-quarter fiscal 2026 10-Q prints a discrete fourth-quarter cash flow statement, so every fourth-quarter cash flow figure here is a subtraction of the nine-month column from the fiscal-year column rather than a reported amount.",
"Neither filing prints a discrete cash flow statement for the third quarter of fiscal 2026 or fiscal 2025, only the nine-month cumulative amounts, which are reported in the year-to-date block. The third-quarter entries therefore carry no cash flow figures.",
"The first and second quarters of fiscal 2026 and fiscal 2025 are not reported. Neither the fiscal 2026 10-K nor the third-quarter fiscal 2026 10-Q prints those quarters.",
"Fiscal 2024 has no full balance sheet in these filings. Only total shareholders' equity and shares outstanding at June 30, 2024, from the consolidated statements of shareholders' equity, are reported for that year.",
"The fiscal 2026 unallocated operating expenses include $8.0 million of acquisition-related expenses and other costs, but the 10-K does not state how much of that, if any, relates to the pending Merck KGaA merger."
],
"headline": {
"period": "FY2026",
"period_end_words": "June 30, 2026",
"metrics": [
{
"label": "Revenue",
"format": "usd",
"value": 1215039000,
"text": "$1.22 billion",
"exact": "$1,215,039,000",
"compact": "$1.22B",
"abs": "$1.22 billion",
"prior_value": 1219635000,
"prior": "$1.22 billion",
"priorabs": "$1.22 billion",
"yoy": "down 0.4%",
"source": {
"array": "annual",
"field": "income_statement.net_sales",
"index": 0,
"period_label": "FY2026",
"period_end": "2026-06-30",
"period_start": "2025-07-01",
"span_days": 364,
"source_accession": "0001104659-26-100322",
"prior_index": 1,
"prior_period_label": "FY2025",
"prior_period_end": "2025-06-30",
"prior_period_start": "2024-07-01",
"prior_span_days": 364,
"prior_source_accession": "0001104659-26-100322",
"gap_days": 365
}
},
{
"label": "Net income",
"format": "usd",
"value": 181862000,
"text": "$181.86 million",
"exact": "$181,862,000",
"compact": "$181.86M",
"abs": "$181.86 million",
"prior_value": 73400000,
"prior": "$73.4 million",
"priorabs": "$73.4 million",
"yoy": "up 147.8%",
"source": {
"array": "annual",
"field": "income_statement.net_earnings",
"index": 0,
"period_label": "FY2026",
"period_end": "2026-06-30",
"period_start": "2025-07-01",
"span_days": 364,
"source_accession": "0001104659-26-100322",
"prior_index": 1,
"prior_period_label": "FY2025",
"prior_period_end": "2025-06-30",
"prior_period_start": "2024-07-01",
"prior_span_days": 364,
"prior_source_accession": "0001104659-26-100322",
"gap_days": 365
}
},
{
"label": "Diluted EPS",
"format": "eps",
"value": 1.16,
"text": "$1.16",
"exact": "$1.16",
"compact": "$1.16",
"abs": "$1.16",
"prior_value": 0.46,
"prior": "$0.46",
"priorabs": "$0.46",
"yoy": "up 152.2%",
"source": {
"array": "annual",
"field": "income_statement.diluted_eps",
"index": 0,
"period_label": "FY2026",
"period_end": "2026-06-30",
"period_start": "2025-07-01",
"span_days": 364,
"source_accession": "0001104659-26-100322",
"prior_index": 1,
"prior_period_label": "FY2025",
"prior_period_end": "2025-06-30",
"prior_period_start": "2024-07-01",
"prior_span_days": 364,
"prior_source_accession": "0001104659-26-100322",
"gap_days": 365
}
},
{
"label": "Operating income",
"format": "usd",
"value": 251890000,
"text": "$251.89 million",
"exact": "$251,890,000",
"compact": "$251.89M",
"abs": "$251.89 million",
"prior_value": 102255000,
"prior": "$102.25 million",
"priorabs": "$102.25 million",
"yoy": "up 146.3%",
"source": {
"array": "annual",
"field": "income_statement.operating_income",
"index": 0,
"period_label": "FY2026",
"period_end": "2026-06-30",
"period_start": "2025-07-01",
"span_days": 364,
"source_accession": "0001104659-26-100322",
"prior_index": 1,
"prior_period_label": "FY2025",
"prior_period_end": "2025-06-30",
"prior_period_start": "2024-07-01",
"prior_span_days": 364,
"prior_source_accession": "0001104659-26-100322",
"gap_days": 365
}
},
{
"label": "Free cash flow",
"format": "usd",
"value": 263223000,
"text": "$263.22 million",
"exact": "$263,223,000",
"compact": "$263.22M",
"abs": "$263.22 million",
"prior_value": 256550000,
"prior": "$256.55 million",
"priorabs": "$256.55 million",
"yoy": "up 2.6%",
"source": {
"array": "annual",
"field": "cash_flow.free_cash_flow",
"index": 0,
"period_label": "FY2026",
"period_end": "2026-06-30",
"period_start": "2025-07-01",
"span_days": 364,
"source_accession": "0001104659-26-100322",
"prior_index": 1,
"prior_period_label": "FY2025",
"prior_period_end": "2025-06-30",
"prior_period_start": "2024-07-01",
"prior_span_days": 364,
"prior_source_accession": "0001104659-26-100322",
"gap_days": 365
}
}
],
"summary": "Bio-Techne reported $1.22 billion in net sales for FY2026, the fiscal year ended June 30, 2026, down 0.4% from a year earlier and leaving the life science tools maker's top line roughly where it stood in fiscal 2025. Net income was $181.86 million, up 147.8%, and operating income was $251.89 million, up 146.3%, but almost all of that increase came from a depressed prior-year base rather than from operating momentum: fiscal 2025 absorbed an impairment on a business classified as held for sale and a non-recurring arbitration award, and fiscal 2026 booked a recovery on that same business. Diluted earnings per share were $1.16, and in June 2026 Bio-Techne agreed to be acquired by Merck KGaA, Darmstadt, Germany, a transaction that was still pending at the date of the annual report.",
"qa": [
{
"q": "How much revenue did Bio-Techne report in FY2026?",
"a": "Bio-Techne reported $1.22 billion in net sales for FY2026, the fiscal year ended June 30, 2026. That is down 0.4% from fiscal 2025 and effectively unchanged, with favorable currency translation offsetting the revenue lost to a divested business."
},
{
"q": "Why did Bio-Techne's net income rise so much in FY2026?",
"a": "Bio-Techne's net income was $181.86 million in FY2026, up 147.8% from $73.4 million a year earlier, but the increase is mostly a prior-year base effect rather than growth in the business. Fiscal 2025 carried an impairment on a business classified as held for sale and a non-recurring arbitration award, while fiscal 2026 recorded a recovery on that business, and operating income moved the same way, to $251.89 million from $102.25 million."
},
{
"q": "What was Bio-Techne's earnings per share in FY2026?",
"a": "Bio-Techne reported diluted earnings per share of $1.16 for FY2026, the fiscal year ended June 30, 2026, against $0.46 in fiscal 2025. As with net income, the year-over-year gain reflects prior-year charges that did not repeat."
},
{
"q": "How much cash did Bio-Techne generate in FY2026?",
"a": "Bio-Techne's free cash flow was $263.22 million in FY2026, the fiscal year ended June 30, 2026, up 2.6% from $256.55 million a year earlier. Cash generation was far steadier than reported earnings across the two years."
}
]
},
"company_details": {
"Name": "BIO-TECHNE Corp",
"Ticker": "TECH",
"CIK": "0000842023",
"Exchange": "Nasdaq",
"State": "Minnesota",
"Incorporation": "Minnesota",
"SIC": "2836",
"Office": "Life Sciences",
"Industry": "Biological Products, (No Diagnostic Substances)"
},
"next_filing": {
"predicted_date": "2026-11-04",
"predicted_type": "10-Q"
},
"fiscal_period": {
"fiscal_year": 2026,
"fiscal_period": "FY",
"tag": "FY26",
"period_end": "2026-06-30",
"form": "10-K",
"accession": "0001104659-26-100322",
"fiscal_year_end": "0630",
"source": "facts"
}
}